<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506387</url>
  </required_header>
  <id_info>
    <org_study_id>BEL 0</org_study_id>
    <nct_id>NCT02506387</nct_id>
  </id_info>
  <brief_title>Belgian Mitraclip Registry</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the registry is to investigate and follow all patients treated with
      the MitraClip System in Belgium. This information is intended to contribute to decision
      making with regards to MitraClip therapy selection in patients with mitral regurgitation: (a)
      by establishing the clinical value of the MitraClip therapy in the continuum of care; and (b)
      by providing practical information that will allow physicians to make therapeutic decisions,
      assist hospitals to make purchasing decisions, and assist insurers/government in making
      coverage decisions.

      In addition national data will be shared with European registries in order to increase the
      knowledge about the efficacy of this new technique.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>residual mitral regurgitation (MR) post mitraclip</measure>
    <time_frame>at day 3-5 post mitraclip implantation</time_frame>
    <description>MR grade 1 tot 4, as assessed on echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac mortality</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>surgical mitral valve intervention</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hospitalization for heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>heart failure as primary reason of hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pericardial effusion</measure>
    <time_frame>day 1-2 after mitraclip implantation</time_frame>
    <description>peri-procedural pericardial effusion with hemodynamic impact as assessed on echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in New York Heart Association (NYHA) classification</measure>
    <time_frame>2 years</time_frame>
    <description>NYHA 1-4 as assessed by the clinician at baseline and 1 month, 6 month, 1 year and 2 year after mitraclip implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance during 6 min walking test</measure>
    <time_frame>1 year</time_frame>
    <description>distance expressed in meters assessed baseline, 6 month and 1 y after mitraclip implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) remodeling</measure>
    <time_frame>6 month</time_frame>
    <description>echocardiac evaluation of LV end diastolic volume (LVEDV) with calculation of LV remodeling according to following formula: (LVEDV at six month - LVEDV baseline)/ LVEDV baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure requiring dialysis</measure>
    <time_frame>up to one month after mitraclip implantation</time_frame>
    <description>Acute renal failure requiring dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urgent surgical mitral valve intervention</measure>
    <time_frame>within 24h after procedure</time_frame>
    <description>urgent surgical mitral valve intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>6 month</time_frame>
    <description>echocardiac evaluation of LV end systolic volume ( LVESV) and LV end diastolic volume (LVEDV) with calculation of LVEF according to following formula: (LVEDV - LVESV)/ LVEDV . LVEF measured at baseline and 6 month after mitraclip implantation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Mitraclip patients</arm_group_label>
    <description>Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mitraclip</intervention_name>
    <description>The decision to implant mitraclip is not part of this observational study but is made by the heart-team.</description>
    <arm_group_label>Mitraclip patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with symptomatic severe mitral regurgitation at too high risk voor cardiac surgery
        and with suitable anatomy for mitraclip implantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe mitral regurgitation

          -  symptomatic (NYHA class&gt;1) despite optimal medical therapy

          -  suitable anatomy for mitraclip implantation

          -  too high risk for cardiac surgery

        Exclusion Criteria:

          -  &lt;1 year life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Claeys, MD, PhD</last_name>
    <phone>003238214706</phone>
    <email>marc.claeys@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Bosmans, MD, PhD</last_name>
    <phone>00328213000</phone>
    <email>johan.bosmans@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Claeys, MD PHD</last_name>
      <phone>003238214706</phone>
      <email>marc.claeys@uantwerpen.be</email>
    </contact>
    <contact_backup>
      <last_name>Bernard Paelinck, MD PHD</last_name>
      <phone>003238213000</phone>
      <email>bernard.paelinck@uza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Vanderheyden, MD, PhD</last_name>
      <phone>0032 53 72 41 11</phone>
      <email>marc.vanderheyden@olvz-aalst.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>August 7, 2016</last_update_submitted>
  <last_update_submitted_qc>August 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>M Claeys</investigator_full_name>
    <investigator_title>Prof dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

